Vor Biopharma financials
$18.33+0.11%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$371.6M | -$121.2M | -$126.0M | -$93.4M | -$69.0M |
| Net income | -$696.0M | -$116.9M | -$117.9M | -$92.1M | -$70.1M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-70.50 | $-34.03 | $-35.00 | $-46.60 | $-42.00 |
| EBITDA | -$368.8M | -$117.7M | -$122.5M | -$90.9M | -$67.6M |
| Operating cash flow | -$142.7M | -$99.7M | -$100.3M | -$85.1M | -$69.1M |
| Free cash flow | -$143.7M | -$99.9M | -$101.4M | -$93.6M | -$73.0M |
| Diluted shares | 9.9M | 3.4M | 3.4M | 2.0M | 1.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $396.5M | $81.9M | $31.4M | $57.7M | $119.8M |
| Short-term investments | $58.7M | $10.0M | $105.8M | $172.5M | $87.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $464.1M | $142.9M | $198.1M | $299.4M | $242.6M |
| Total liabilities | $628.4M | $46.2M | $47.4M | $48.8M | $26.3M |
| Shareholders' equity | -$164.3M | $96.7M | $150.7M | $250.6M | $216.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology